A study of the long-term safety and mechanism of action of alemtuzumab, an experimental drug used in Multiple Sclerosis
Study code
CBR74
Lead researcher
Dr. Anu Kemppinen
Study type
Participant re-contact
Institution or company
University of Cambridge
Researcher type
Academic
Speciality area
Neurological Disorders
Recruitment Site
Cambridge
Summary
This research study is looking at genes that control the immune system, which have been identified as being important in the disease called multiple sclerosis. The main purpose of this study is to see how these genes influence the effectiveness of an experimental drug (alemtuzumab) in the treatment of Multiple Sclerosis.
Participation: For this study we recruited 14 healthy volunteers from the Cambridge BioResource to attend a single appointment where they gave 50 ml of blood.
Organisation: This study is organised by Dr Anu Kemppinen from the Univeristy of Cambridge.